After the amyloid tracer [18F] florbetaben injection (brand name: AV-1) received approval from China's National Medical Products Administration, UV Clinic Beijing became one of the first partner institutions to apply it. Nearly a year of practice has built substantial clinical experience. The tracer can move the early diagnosis of Alzheimer's disease forward by 15 to 20 years, adding strong technological momentum to prevention and control in northern China.
Three Core Advantages
- High sensitivity and specificity. Amyloid-beta is a key marker of Alzheimer's disease; the tracer binds to it with great specificity, detecting pathological deposits in the brain and signalling risk 15 to 20 years before dementia symptoms appear.
- Controllable safety. It meets national radiation-safety standards and has shown good tolerability in clinical use.
- Non-invasive visualisation. PET imaging clearly and non-invasively displays abnormal amyloid deposition, providing direct imaging evidence and helping doctors monitor progression and plan individual treatment.
The Disease Burden and Risk Stratification
From 1990 to 2021, deaths from Alzheimer's disease among people over 65 in China rose from 109,000 to 470,000, and the number of patients worldwide is projected to exceed 82 million by 2030. Risk factors fall into two groups: non-modifiable factors (about 60 percent), including age over 65, female susceptibility, the APOE4 gene and family history; and modifiable factors (about 40 percent), largely lifestyle-related. Risk screening therefore needs precise stratification - ruling out pseudo-cognitive impairment, avoiding misdiagnosis and tailoring interventions.
A Clinical Case in Beijing
UV Clinic Beijing recently assessed an 80-year-old woman whose symptoms closely matched Alzheimer's disease. She had memory loss, low mood and a history of diabetes and high lipids; when diagnosed in October 2024 she scored 23 on the MMSE and 15 on the MoCA, with reduced blood amyloid-beta 1-42 and a normal P-tau181. Amyloid PET imaging took about 90 minutes and showed increased cortical uptake consistent with a positive amyloid scan, together with lacunar and infarct lesions suggesting cerebrovascular disease. The result supported the clinical diagnosis and gave the treating team precise imaging evidence for adjusting medication and planning follow-up.
The center is equipped with high-end Siemens Healthineers PET/CT and PET/MR systems offering 1-2 millimetre spatial resolution, able to visualise key amyloid-deposition regions such as the cerebral sulci and hippocampus and detect tiny plaques below 2 mm. When an abnormality is found, patients can be referred to neurology specialists from the Mingyihui expert network for diagnosis and a follow-up plan.
A Seat in the Alzheimer's Industry Alliance
In August 2025, China's first Alzheimer's disease industry ecosystem alliance was launched in Changsha, bringing together leading institutions across diagnostics, drug development, medical imaging and health management. UV Clinic was appointed a founding council member - the only medical imaging diagnostic center in the alliance - recognising its work in Alzheimer's prevention and care.
This article is general health information based on a case-sharing example and is not medical advice. Any post-processing data analysis report is based on the images from that examination and the information provided, is for clinical reference only, and the final imaging diagnostic report prevails. Please follow your treating physician's instructions for any examination or treatment decision, and consult a qualified clinician before changing medication or follow-up plans.